Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.
Higher Radiation Dose Reduces "Biochemical Recurrence" of Prostate Cancer
(Posted: 10/03/2005, Updated: 03/15/2010) - Men with early-stage prostate cancer who received higher doses of radiation were less likely than men who received the conventional dose to have rising levels of prostate-specific antigen (PSA), a phenomenon referred to as “biochemical recurrence,” according to the March 1, 2010, issue of Journal of Clinical Oncology.
Shorter Course of Radiation Effective and Safe for Some Women with Early-stage Breast Cancer
(Posted: 03/15/2010) - Giving radiation therapy in fewer but larger doses may be an alternative to standard radiation therapy for some women with early-stage breast cancer, according to a study published in the February 11, 2010, New England Journal of Medicine.
Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer
(Posted: 03/15/2010) - Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published in the January 30, 2010, Lancet.
Cetuximab (Erbitux®) Plus Radiation Beneficial for Patients with Head and Neck Cancer
(Posted: 06/05/2004, Updated: 02/25/2010) - Compared to radiation alone, cetuximab plus radiation therapy improves overall survival of patients with advanced head and neck cancer that has not spread to other parts of the body, according to an article published online November 7, 2009, in Lancet Oncology.